MPI8
MPI8 (TG0205221) is an inhibitor of the major protease of SARS-CoV-2 (MPro) with high antiviral activity. MPI8 exerts its antiviral effect by dual and selective inhibition of SARS-CoV-2 MPro and host cell cysteine protease L (cathepsin L). MPI8 can be used in clinical studies of COVID-19.
For research use only. We do not sell to patients.
- CAS No.: 856242-63-2
- Formula: C32H48N4O7
- Molecular Weight:600.75
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All Cathepsin Isoforms
More
Biological Activity
Description
IC50 & Target
|
SARS-CoV‑2 Main Protease |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK-293T | CC50 |
70 μM
Compound: MPI8
|
Cytotoxicity against HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38608245] |
| Vero C1008 | CC50 |
>200 μM
Compound: 105
|
Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability by CCK8 assay
Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability by CCK8 assay
|
[PMID: 34798775] |
Chemical Information
-
CAS No. 856242-63-2
-
Molecular Weight 600.75
-
Formula C32H48N4O7
-
SMILES
O=C(N[C@H](C(N[C@H](C(N[C@H](C=O)C[C@H]1C(NCC1)=O)=O)CC2CCCCC2)=O)[C@@H](C)OC(C)(C)C)OCC3=CC=CC=C3
-
Synonyms
TG0205221
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
[1]. Ma X R, et al. MPI8 is potent against SARS‐CoV‐2 by inhibiting dually and selectively the SARS‐CoV‐2 main protease and the host cathepsin L[J]. ChemMedChem, 2022, 17(1): e202100456. [Content Brief]
[2]. Yang S, et al. Synthesis, crystal structure, structure− activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor[J]. Journal of medicinal chemistry, 2006, 49(16): 4971-4980. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MPI8 Related Classifications
HY-158763 Related Classifications
Powered by Bioz